Logo image of CARA

CARA THERAPEUTICS INC (CARA) Stock Fundamental Analysis

NASDAQ:CARA - Nasdaq - US1407551092 - Common Stock

4.6  -0.05 (-1.08%)

Fundamental Rating

3

CARA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for CARA as it has an excellent financial health rating, but there are worries on the profitability. CARA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CARA has reported negative net income.
In the past year CARA has reported a negative cash flow from operations.
In the past 5 years CARA reported 4 times negative net income.
CARA had a negative operating cash flow in each of the past 5 years.
CARA Yearly Net Income VS EBIT VS OCF VS FCFCARA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M -60M -80M -100M

1.2 Ratios

CARA has a Return On Assets of -186.10%. This is amonst the worse of the industry: CARA underperforms 88.17% of its industry peers.
CARA has a worse Return On Equity (-13511.32%) than 87.10% of its industry peers.
Industry RankSector Rank
ROA -186.1%
ROE -13511.32%
ROIC N/A
ROA(3y)-58.96%
ROA(5y)-43.89%
ROE(3y)-100.1%
ROE(5y)-70.78%
ROIC(3y)N/A
ROIC(5y)N/A
CARA Yearly ROA, ROE, ROICCARA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100 -150 -200

1.3 Margins

The Gross Margin of CARA (170.32%) is better than 100.00% of its industry peers.
The Profit Margin and Operating Margin are not available for CARA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 170.32%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CARA Yearly Profit, Operating, Gross MarginsCARA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10K -20K -30K -40K -50K

More info and screens

7

2. Health

2.1 Basic Checks

CARA does not have a ROIC to compare to the WACC, probably because it is not profitable.
CARA has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, CARA has less shares outstanding
There is no outstanding debt for CARA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CARA Yearly Shares OutstandingCARA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
CARA Yearly Total Debt VS Total AssetsCARA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -21.49, we must say that CARA is in the distress zone and has some risk of bankruptcy.
CARA has a Altman-Z score of -21.49. This is amonst the worse of the industry: CARA underperforms 87.10% of its industry peers.
CARA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -21.49
ROIC/WACCN/A
WACC10.7%
CARA Yearly LT Debt VS Equity VS FCFCARA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

CARA has a Current Ratio of 4.77. This indicates that CARA is financially healthy and has no problem in meeting its short term obligations.
CARA has a better Current ratio (4.77) than 63.44% of its industry peers.
CARA has a Quick Ratio of 4.71. This indicates that CARA is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 4.71, CARA is doing good in the industry, outperforming 65.05% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.77
Quick Ratio 4.71
CARA Yearly Current Assets VS Current LiabilitesCARA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

CARA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.60%, which is quite good.
Looking at the last year, CARA shows a very negative growth in Revenue. The Revenue has decreased by -59.22% in the last year.
The Revenue has been growing by 9.21% on average over the past years. This is quite good.
EPS 1Y (TTM)18.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.77%
Revenue 1Y (TTM)-59.22%
Revenue growth 3Y-46.26%
Revenue growth 5Y9.21%
Sales Q2Q%-47.47%

3.2 Future

CARA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.48% yearly.
CARA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.12% yearly.
EPS Next Y39.95%
EPS Next 2Y28.05%
EPS Next 3Y19.43%
EPS Next 5Y11.48%
Revenue Next Year-82.49%
Revenue Next 2Y-63.76%
Revenue Next 3Y-62.03%
Revenue Next 5Y13.12%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CARA Yearly Revenue VS EstimatesCARA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M
CARA Yearly EPS VS EstimatesCARA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 -1 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CARA. In the last year negative earnings were reported.
Also next year CARA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CARA Price Earnings VS Forward Price EarningsCARA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CARA Per share dataCARA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as CARA's earnings are expected to grow with 19.43% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.05%
EPS Next 3Y19.43%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CARA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARA THERAPEUTICS INC

NASDAQ:CARA (1/21/2025, 8:00:00 PM)

4.6

-0.05 (-1.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)N/A N/A
Inst Owners32.75%
Inst Owner Change-0.11%
Ins Owners2.07%
Ins Owner Change-0.25%
Market Cap252.36M
Analysts45.71
Price TargetN/A
Short Float %N/A
Short Ratio0.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.9%
Min EPS beat(2)-32.39%
Max EPS beat(2)8.59%
EPS beat(4)1
Avg EPS beat(4)-25.54%
Min EPS beat(4)-40.4%
Max EPS beat(4)8.59%
EPS beat(8)3
Avg EPS beat(8)-21.19%
EPS beat(12)5
Avg EPS beat(12)-9.66%
EPS beat(16)8
Avg EPS beat(16)19.79%
Revenue beat(2)1
Avg Revenue beat(2)18.9%
Min Revenue beat(2)-17.21%
Max Revenue beat(2)55%
Revenue beat(4)2
Avg Revenue beat(4)-1.78%
Min Revenue beat(4)-68.74%
Max Revenue beat(4)55%
Revenue beat(8)4
Avg Revenue beat(8)-14.3%
Revenue beat(12)7
Avg Revenue beat(12)-7.93%
Revenue beat(16)9
Avg Revenue beat(16)-0.79%
PT rev (1m)0.99%
PT rev (3m)1.49%
EPS NQ rev (1m)0%
EPS NQ rev (3m)25.49%
EPS NY rev (1m)0%
EPS NY rev (3m)0.32%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)22.13%
Revenue NY rev (1m)-27.54%
Revenue NY rev (3m)-26.93%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 29.05
P/FCF N/A
P/OCF N/A
P/B 356.94
P/tB 356.94
EV/EBITDA N/A
EPS(TTM)-1.75
EYN/A
EPS(NY)-0.79
Fwd EYN/A
FCF(TTM)-1.41
FCFYN/A
OCF(TTM)-1.35
OCFYN/A
SpS0.16
BVpS0.01
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -186.1%
ROE -13511.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 170.32%
FCFM N/A
ROA(3y)-58.96%
ROA(5y)-43.89%
ROE(3y)-100.1%
ROE(5y)-70.78%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1144.28%
Cap/Sales 35.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.77
Quick Ratio 4.71
Altman-Z -21.49
F-Score4
WACC10.7%
ROIC/WACCN/A
Cap/Depr(3y)316.33%
Cap/Depr(5y)225.13%
Cap/Sales(3y)3.87%
Cap/Sales(5y)2.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.77%
EPS Next Y39.95%
EPS Next 2Y28.05%
EPS Next 3Y19.43%
EPS Next 5Y11.48%
Revenue 1Y (TTM)-59.22%
Revenue growth 3Y-46.26%
Revenue growth 5Y9.21%
Sales Q2Q%-47.47%
Revenue Next Year-82.49%
Revenue Next 2Y-63.76%
Revenue Next 3Y-62.03%
Revenue Next 5Y13.12%
EBIT growth 1Y33.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year38.83%
EBIT Next 3Y12.76%
EBIT Next 5Y8.58%
FCF growth 1Y-36.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.47%
OCF growth 3YN/A
OCF growth 5YN/A